Drug intelligence / Profile preview

Fusion-TAC

Development stage: Unknown
Lead developer: ViferaXS
Modality: Vaccines & Immunotherapeutics
Administration: Intravenous, Injection

Overview

Fusion-TAC is a T-cell activating immunotherapy developed by ViferaXS for the treatment of Fibrolamellar Carcinoma (FLC). The drug is designed to direct the immune system, specifically T cells, against neoepitopes derived from the unique fusion proteins characteristic of Fibrolamellar Carcinoma, such as the DNAJB1-PRKACA fusion. By targeting these tumor-specific neoantigens, Fusion-TAC aims to induce a potent and selective anti-tumor immune response. It is currently being evaluated in Phase 1/2 clinical trials.

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on Fusion-TAC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fusion-TAC.

Explore the full profile